Zobrazeno 1 - 10
of 1 494
pro vyhledávání: ''
Autor:
Yue Lu, Rui-Juan Sun, Jian-Ping Zhang, Fang Xu, Zhi-Cong Du, Ge-Le Tong, Yun Wang, Dao-Pei Lu
Publikováno v:
Leukemialymphoma. 63(13)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic malignancy characterized by poor prognosis even following an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed 15 patients diagnose
Autor:
Prajwal Dhakal, Utsav Joshi, Elizabeth Lyden, Avantika Pyakuryal, Krishna Gundabolu, Vijaya Raj Bhatt
Publikováno v:
Leukemialymphoma. 63(11)
Understanding the association between insurance status and survival in an evolving US healthcare system remains a challenge but is essential to address healthcare disparities. We utilized National Cancer Database to evaluate the effects of insurance
Autor:
Masuho Saburi, Masanori Sakata, Hiroyuki Takata, Yasuhiko Miyazaki, Katsuya Kawano, Hitohiro Sasaki, Miyuki Abe, Kazuhiro Kohno, Yasuhiro Soga, Kentaro Nagamatsu, Keiji Ono, Toshiyuki Nakayama, Eiichi Ohtsuka
Publikováno v:
Leukemialymphoma. 63(11)
Publikováno v:
Leukemialymphoma. 63(10)
Secondary central nervous system lymphoma (SCNSL) affects approximately 5% of patients with aggressive large B-cell lymphoma (LBCL) and is associated with poor outcomes. This retrospective, multicenter study included 62 consecutive patients with SCNS
Publikováno v:
Leukemialymphoma. 63(9)
The frailty index (FI) predicts clinical outcomes in oncology. However, in the acute myeloid leukemia (AML) setting, its predictive ability is poorly understood. We assessed whether the FI predicts complete remission (CR), intensive care unit (ICU) a
Autor:
Estella Matutes, Aaron Polliack
Publikováno v:
Leukemialymphoma. 63(6)
Publikováno v:
Leukemialymphoma. 63(7)
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes. In this study, data of 84 DLBCL patients, who were tested EBV DNA in peripheral blood, were retrospectively analyzed. Patients were divided into three subgroups
Autor:
Andrea Rivero, Alfredo Rivas-Delgado, Laura Magnano, Armando López-Guillermo, Pablo Mozas, Neus Villamor, Elias Campo, Patricia Pérez-Galán, Julio Delgado, Eva Giné, Ferran Nadeu
Publikováno v:
Leukemialymphoma. 63(4)
The Prognostic Nutritional Index (PNI), a parameter combining serum albumin concentration and absolute lymphocyte count, is considered a measure of the nutritional and inflammatory status and the host's anti-tumor response. We analyzed the clinical c
Autor:
Moshe Mittelman, Yehonatan Sherf, Daniela Goldstein, Tamar Tadmor, Tamar Berger, Reut Harel, Orit Sofer, Eran Zimran, Nagib Dally, Jabour Halloun, Merav Leiba, Gilad Itchaki, Andrei Braester, Maya Koren-Michowitz, Martin Ellis, Nadav Sarid, Shlomzion Aumann, Lev Shvidel, Tsila Zuckerman, Itai Levi, Avital Lavi, Ofer Shpilberg, Ariel Aviv, Noa Lavi, Sharon Ben Barouch, Pia Raanani, Ilana Levy, Katrin Herzog Tzarfati, Sigal Grisariu, Shay Yeganeh, Celia Suriu, Osnat Dolberg Jarchowsky
Publikováno v:
Leukemialymphoma. 62(14)
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory dat
Autor:
Kemal Haque, Loretta J. Nastoupil, Jason R. Westin, Letitia Lensun, Michael Wang, Sattva S. Neelapu, Hilary McElwaine-Johnn, Felipe Samaniego, Hun Ju Lee, James Dow, Nathan Fowler, Alexander Richard Liam Cecil, Richard E. Davis, Andrew David Whale, Elisabeth A. Bone, Fredrick B. Hagemeister, Philip A Beer, Franck Alexandre Silva
Publikováno v:
Leukemialymphoma. 62(14)
PI3-kinase p110δ is mainly expressed in lymphocytes and is an attractive therapeutic target in B cell lymphomas. Targeting p110β may further suppress tumor growth and overcome escape mechanisms. KA2237 is an oral, potent, dual p110β/p110δ inhibit